ABSTRACT
Advanced glycation end products (AGEs) are formed when glucose reacts nonenzymatically with proteins; these modifications are implicated in aging and pathogenesis of many age-related diseases including type II diabetes, atherosclerosis, and neurodegenerative disorders. Thus, pharmaceutical interventions that can reduce AGEs may delay age-onset diseases and extend lifespan. Using LC-MS(E), we show that rifampicin (RIF) reduces glycation of important cellular proteins in vivo and consequently increases lifespan in Caenorhabditis elegans by up to 60%. RIF analog rifamycin SV (RSV) possesses similar properties, while rifaximin (RMN) lacks antiglycation activity and therefore fails to affect lifespan positively. The efficacy of RIF and RSV as potent antiglycating agents may be attributed to the presence of a p-dihydroxyl moiety that can potentially undergo spontaneous oxidation to yield highly reactive p-quinone structures, a feature absent in RMN. We also show that supplementing rifampicin late in adulthood is sufficient to increase lifespan. For its effect on longevity, rifampicin requires DAF-18 (nematode PTEN) as well as JNK-1 and activates DAF-16, the FOXO homolog. Interestingly, the drug treatment modulates transcription of a different subset of DAF-16 target genes, those not controlled by the conserved Insulin-IGF-1-like signaling pathway. RIF failed to increase the lifespan of daf-16 null mutant despite reducing glycation, showing thereby that DAF-16 may not directly affect AGE formation. Together, our data suggest that the dual ability to reduce glycation in vivo and activate prolongevity processes through DAF-16 makes RIF and RSV effective lifespan-extending interventions.
Subject(s)
Aging , Antibiotics, Antitubercular/pharmacology , Caenorhabditis elegans Proteins/metabolism , Caenorhabditis elegans/metabolism , Forkhead Transcription Factors/metabolism , Glycation End Products, Advanced/metabolism , Longevity/drug effects , Rifampin/pharmacology , Animals , Caenorhabditis elegans/drug effects , Caenorhabditis elegans/genetics , Insulin/metabolism , Mutation/genetics , Signal Transduction/drug effects , Signal Transduction/geneticsABSTRACT
The non-enzymatic reaction between glucose and protein can be chemically reversed by transglycation. Here we report the transglycation activity of hydralazine using a newly developed MALDI-TOF-MS based assay. Hydralazine mediated transglycation of HbA1c, plasma proteins and kidney proteins was demonstrated in streptozotocin (STZ) induced diabetic mice, as evidenced by decrease in protein glycation, as well as presence of hydralazine-glucose conjugate in urine of diabetic mice treated with hydralazine. Hydralazine down regulated the expression of Receptor for Advanced Glycation End products (RAGE), NADPH oxidase (NOX), and super oxide dismutase (SOD). These findings will provide a new dimension for developing intervention strategies for the treatment of glycation associated diseases such as diabetes complications, atherosclerosis, and aging.
Subject(s)
Diabetes Mellitus, Experimental/metabolism , Glycation End Products, Advanced/metabolism , Hydralazine/pharmacology , Proteome/metabolism , Animals , Blood Urea Nitrogen , Cholesterol/blood , Creatinine/blood , Diabetes Mellitus, Experimental/chemically induced , Glycation End Products, Advanced/blood , Glycosylation/drug effects , Humans , Kidney/drug effects , Kidney/metabolism , Male , Mice , NADPH Oxidases/metabolism , Proteomics/methods , Streptozocin/adverse effects , Superoxide Dismutase/metabolism , Triglycerides/bloodABSTRACT
Albumin is one of the most abundant plasma proteins and is heavily glycated in diabetes. In this study, we have addressed whether variation in the albumin levels influence glycation of plasma proteins and HbA1c. The study was performed in three systems: (1) streptozotocin (STZ)-induced diabetic mice plasma, (2) diabetic clinical plasma, and (3) in vitro glycated plasma. Diabetic mice and clinical plasma samples were categorized as diabetic high albumin plasma (DHAP) and diabetic low albumin plasma (DLAP) on the basis of their albumin levels. For the in vitro experiment, two albumin levels, high albumin plasma (HAP) and low albumin plasma (LAP), were created by differential depletion of plasma albumin. Protein glycation was studied by using a combination of two-dimensional electrophoresis (2DE), Western blotting, and LC-MS(E). In both mice and clinical experiments, an increased plasma protein glycation was observed in DLAP than in DHAP. Additionally, plasma albumin levels were negatively correlated with HbA1c. The in vitro experiment with differential depletion of albumin mechanistically showed that the low albumin levels are associated with increased plasma protein glycation and that albumin competes for glycation with other plasma proteins.
Subject(s)
Diabetes Mellitus/blood , Glycated Hemoglobin/metabolism , Glycoproteins/blood , Serum Albumin/metabolism , Animals , Blood Glucose/metabolism , Blotting, Western , Cluster Analysis , Diabetes Mellitus, Experimental/blood , Electrophoresis, Gel, Two-Dimensional , Glycated Hemoglobin/chemistry , Glycation End Products, Advanced/chemistry , Glycation End Products, Advanced/metabolism , Glycoproteins/chemistry , Glycosylation , Humans , Mice , Mice, Inbred BALB C , Models, Biological , Proteomics , Serum Albumin/chemistryABSTRACT
An in vitro insulin glycation assay was developed for screening glycation inhibitors. The assay involves the use of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for monitoring the formation of glycated insulin. The assay is simple, rapid and amenable for high throughput screening. Using this assay we have discovered a strong anti-glycation activity for the anti-tuberculosis drug rifampicin. These results were compared with bovine serum albumin glucose fluorescence assay. In addition, the IC(50) of rifampicin was lower than that of aminoguanidine, a known anti-glycating agent, suggesting that rifampicin is a more potent glycation inhibitor.
